• Users Online: 250
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Instructions to authors Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2022  |  Volume : 9  |  Issue : 1  |  Page : 10-16

Mucormycosis, COVID-19, and immunosuppression – The three sides of similar triangle: Narrative review


Daswani Dental College and Research Centre, Kota, Rajasthan, India

Correspondence Address:
Dr. Vijayata Jayprakash Singh
Daswani Dental College and Research Centre, Kota - 324 005, Rajasthan
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/sjoralsci.sjoralsci_56_21

Rights and Permissions

Introduction: More than two years into the COVID 19 pandemic, medical fraternity each day is facing renewed challenges. Mucormycosis has historically been prevalent in the various parts of world but did not had any diagnostic opportunity before the turn of 20th century. Immunosuppression in any form was always and will forever be the most important ingredients in this disease recipe. Minimally invasive diagnoses with aggressive antimicrobials in addition to the removal of immunosuppression factor are the golden standard of treatment, as oral and maxillofacial surgeons we acknowledge that surgical debridement and various other relatively newer adjunctive therapies have overall reduced the fatal outcomes for such a lethal disease. Aim: This review article focuses on gathering data in relation to immunosuppression due to whatsoever reason and pathogenesis, management, and chance of positive prognosis for patient suffering from mucormycosis . Including surgical and prosthetic options which ascertain descent quality of life for the patient. Materials and Methods: Existing data compilation including the latest research and co-relation of various types of immunosuppression as a nidus for mucormycosis, including the role of novel covid-19 from all relevant electronic databases. Results: Definite co-relation has been stablished for diabetes melitus and covid-19 and speculative co-relation for various types of malignancy and various conditions. Discussion: A strong immunity is an antagonist for mucormycosis, and new advances in field of medicine and surgery have changed the grim look of past where this disease had a 50% mortality rate. Conclusion: Existing literature supports immunosuppression in any form as a nidus for mucormycosis, still further, elaborate research and development is required for identifying the particular cocktail for different diseases process.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1300    
    Printed78    
    Emailed0    
    PDF Downloaded138    
    Comments [Add]    

Recommend this journal